Intraductal mucin-hypersecreting neoplasms of the pancreas

Rickaert, Fabienne; Cremer, Michel; Devière, Jacques; Tavares, L.; Lambilliotte, J.-P.; Schröder, S.; Wurbs, D; Klöppel, Günter

doi:10.1016/0016-5085(91)90032-g

Cited by 204 publications

(103 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should be noted that this entity is distinct from a recently described tumour-associated trypsinogen (Koivunen et al, 1991a, b). Moreover, the changes observed in the present study may be explicable on the basis of the cell of origin of the tumour, because it is considered that pancreatic invasive ductal adenocarcinomas probably arise from small-sized pancreatic ducts or centroacinar cells (Pour, 1985(Pour, , 1988, whereas the so-called intraductal adenocarcinomas of the pancreas probably arise from large-sized pancreatic ducts (Conley et al, 1987;Rickaert et al, 1991).…”

Section: Discussionmentioning

confidence: 70%

Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions

Ohta

Terada²,

Nagakawa³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

Summary Expression of pancreatic trypsinogen and cathepsin B in 23 surgically resected pancreatic ductal adenocarcinomas was evaluated immunohistochemically, using a monoclonal antibody against human pancreatic trypsinogen and a polyclonal antibody against human cathepsin B. Fifteen of 20 invasive tubular adenocarcinomas (75%) expressed pancreatic trypsinogen in a coarse granular pattern located in the supranuclear cytoplasm of the carcinoma cells. In addition, metastatic lesions, including those in peripancreatic lymph nodes and neural plexuses, expressed pancreatic trypsinogen. In contrast, three intraductal (noninvasive) papillary adenocarcinomas did not express pancreatic trypsinogen. Cathepsin B expression was recognised in 14 of 20 invasive tubular adenocarcinomas (70%) in a fine granular pattern located diffusely in the cytoplasm of the carcinoma cells, while none of the three intraductal papillary adenocarcinomas had detectable cathepsin B. These findings suggest that pancreatic invasive ductal adenocarcinomas express pancreatic trypsinogen and cathepsin B immunoreactive peptides, raising the possibility that pancreatic trypsinogen and cathepsin B may act independently of each other in the process of carcinoma invasion and metastasis, like other different classes of proteases involved in the proteolytic modification of the matrix barrier.Pancreatic trypsinogen is one of the proteolytic enzymes produced by pancreatic acinar cells. A recent study (Miszczuk-Jamska et al., 1991) has shown that a new human pancreatic adenocarcinoma cell line (CFPAC-1) and a previously established human pancreatic carcinoma cell line (CAPAN-1) produce human pancreatic trypsinogen. This enzyme is a target protease for pancreatic secretory trypsin inhibitor (PSTI). Tumour-associated trypsinogen is also known to be a serine protease produced by malignant tumour cells, and is believed to play an essential role in cancer invasion and metastasis by degrading trypsin-sensitive extracellular matrix components (Tryggvason et al., 1987;Koivunen et al., 1991a). Tumour-associated trypsinogen has been identified as a target protease for a tumour-associated trypsin inhibitor (TATI), also referred to as PSTI (Huhtala et al., 1982;Halila et al., 1988;Stenman et al., 1988). A recent study (Koivunen et al., 1989) has shown that tumourassociated trypsinogen and pancreatic trypsinogen are similar with respect to amino-terminal sequence, molecular weight and immunoreactivity, but that significant differences exist with respect to isoelectrophoretic mobility and stability. Therefore, it is possible that pancreatic trypsinogen may also take part in the protease cascade associated with tumour invasion and metastasis. It is currently not known whether the differences between tumour-associated trypsinogen and pancreatic trypsinogen are a result of tissue-specific trypsinogen modification or distinct genes.We have therefore evaluated the presence or absence of pancreatic trypsinogen immunohistochemically in 23 surgically resected pancreatic ductal adeno...

show abstract

Section: Discussionmentioning

confidence: 70%

Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions

Ohta

Terada²,

Nagakawa³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Intraductal papillary mucinous tumors are distinguished from the more common cystic neoplasm because they can communicate with the main and/or branch ducts and have a far more favorable prognosis. Although many reports about this tumor have appeared, 2,[4][5][6][7][8][9][10][11][12][13][14][15][16][17] various issues, such as symptoms, diagnosis, prognosis, and selection of the most appropriate mode of surgical management, remain to be clarified. In terms of classification, there has been controversy about whether IPN and MDE represent 2 distinct tumors or the same clinicopathologic entity.…”

Section: Discussionmentioning

confidence: 99%

Intraductal Papillary Mucinous Tumors of the Pancreas Comprise 2 Clinical Subtypes

Kobari

Egawa

Shibuya³

et al. 1999

Arch Surg

314

193

View full text Add to dashboard Cite

show abstract

“…Only one case was diagnosed as ''positive for malignancy'' by cytologic examination, and ductectatic cystadenoma and cystadenocarcinoma) due to its characteristic pancreatograms. [1][2][3][4][5][6][7][8] and was finally diagnosed as adenoma by resected specimens. There was no apparent correlation bePositive results for a ras mutation were obtained in 100% (4 of 4) of malignant IPMT (carcinoma), and in tween the location (main pancreatic duct vs. branch) of the tumor and the presence of K-ras gene muta-88% (8 of 9) of benign IPMT (adenoma).…”

Section: Discussionmentioning

confidence: 99%

Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas

Kondo¹,

Sugano

Fukayama

et al. 1997

Cancer

View full text Add to dashboard Cite

Intraductal mucin-hypersecreting neoplasms of the pancreas

Cited by 204 publications

References 15 publications

Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions

Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions

Intraductal Papillary Mucinous Tumors of the Pancreas Comprise 2 Clinical Subtypes

Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas

Contact Info

Product

Resources

About